Evidence map›Paper›PMID 27822622›Full record

ReviewDer Internist2016

[Diagnostics and treatment of cholangiocellular carcinoma].

L Zender, N P Malek

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

L ZenderMedizinische Klinik I (Gastroenterologie, Hepatologie und Infektiologie), Medizinische Universitätsklinik, Eberhard Karls Universität Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland. lars.zender@med.uni-tuebingen.de.
N P MalekMedizinische Klinik I (Gastroenterologie, Hepatologie und Infektiologie), Medizinische Universitätsklinik, Eberhard Karls Universität Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland.
University of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocellular carcinoma (CCA) is the second most frequent primary liver carcinoma and is an aggressive tumor, which is mostly diagnosed in advanced stages. The overall survival is poor. Histpathological analysis of tumor biopsies or cytological analysis of biliary brushings can be used to confirm the diagnosis. A differentiation is made between distal, perihilar and intrahepatic CCA. The anatomical position determines the diagnostic and therapeutic strategy. Before diagnostic or therapeutic measures are undertaken it is essential to resolve biliary obstruction via endoscopic stenting or percutaneous biliary drainage. Depending on the tumor stage curative treatment options comprise radical surgical resection with hepaticojejunostomy or in selected cases liver transplantation. For intrahepatic or distal CCA liver transplantation is not indicated. In the palliative setting systemic chemotherapy with gemcitabine and cisplatin leads to a significant improvement in survival time.

Indexed as

Antineoplastic AgentsBile Duct NeoplasmsCholangiocarcinomaCombined Modality TherapyDrainageEndoscopy, Digestive SystemEvidence-Based MedicineHepatectomyHumansLiver TransplantationTreatment OutcomeAntineoplastic AgentsBiopsy, bile ductsCholestasisGemcitabine/cisplatinLiver transplantationSurgery, cholangiocellular carcinoma

Identifiers

PMID27822622
OpenAlexW2553967870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.